If you have a 90-day window before an anticipated inspection, or if your facility is overdue for one, this checklist gives you a structured approach to finding and closing the gaps that most commonly generate FDA”>https://www.cloudtheapp.com/glossary-fda-form-483-inspection-observation/”>FDA Form 483 observations.

What FDA inspectors look for under QMSR

The FDA Quality Management System Regulation (QMSR), which took effect in February 2026, aligns 21 CFR Part 820 with ISO 13485:2016. Under QMSR, FDA investigators evaluate the quality management system as a whole, not individual procedures in isolation. They want to see that your processes are documented, implemented consistently, and producing measurable results.

The most frequently cited areas in FDA inspections of device manufacturers include:

• CAPA systems — Are corrective and preventive actions initiated promptly, investigated thoroughly, and verified as effective?
• Complaint handling — Are all complaints captured, classified, and evaluated for MDR reportability?
• Design controls — Do design history files contain complete evidence of design verification and validation?
• Document control — Are procedures current, accessible to staff who use them, and protected from unauthorized changes?
• Supplier qualification — Are critical suppliers approved, monitored, and periodically re-evaluated?
• Training records — Can you demonstrate that personnel performing quality-critical tasks are qualified and trained for those specific roles?

An investigator who finds problems in one area will typically expand the inspection scope. A single gap in CAPA documentation can trigger a full review of complaint files, audithttps://www.cloudtheapp.com/glossary-audits/”>audit> records, and training histories.

• Is the root”>https://www.cloudtheapp.com/glossary-root-cause-investigation/”>root cause investigation complete and documented?
• Is the corrective action defined with an assigned owner and a realistic due date?
• Have effectiveness checks been scheduled?

Close CAPAs that can be resolved quickly. For complex items, document a clear timeline and visible evidence of active progress. A backlog with no movement is one of the most reliable predictors of a 483 observation.

Review your document control system

Walk through your most critical procedures: SOPs covering CAPA, complaints, design controls, supplier qualification, training, and internal audits. Check whether:

• All documents are at their current approved revision
• Obsolete versions have been removed from work areas and controlled storage
• All recent changes are documented with rationale and reviewed by appropriate personnel

Pay particular attention to procedures updated after a previous inspection finding. FDA investigators sometimes return to verify those specific changes were actually implemented.

Verify training records match your current workforce

Investigators routinely ask to see training records for specific employees who perform regulated tasks. If your training matrix does not reflect current job roles, or if records are missing for recently hired or promoted staff, close those gaps now.

Training that happened but was never recorded is treated the same as training that never happened. That distinction matters during an inspection.

Month 3: Simulate the inspection

Run a focused internal audit

Conduct a focused internal audithttps://www.cloudtheapp.com/glossary-audits/”>audit> using FDA’s published guidance and QMSR requirements to review the areas most commonly cited in 483 observations. Assign a cross-functional team and have them review records the way an FDA investigator would: by sampling specific products, specific date ranges, and specific personnel files.

Document every finding with an audit”>https://www.cloudtheapp.com/glossary-audit-finding/”>audit finding record. Then open CAPAs for anything material.

This exercise serves two purposes. It closes real gaps before the inspector arrives. It also gives your team practice locating and presenting their own records under time pressure, which matters when an investigator asks for something specific and expects a response within minutes.

Develop your inspection plan

Every facility should have a documented process for receiving FDA investigators. Your inspection”>https://www.cloudtheapp.com/glossary-inspection-plan/”>inspection plan should cover:

• Who greets the investigator and confirms their credentials
• Which room is designated as the inspection workspace
• How document requests are handled and logged
• Who is responsible for reviewing documents before they are provided
• How responses to verbal observations are coordinated across your quality team

Review this plan with relevant staff well before an inspection is anticipated. The first time your team learns what to do should not be the day an investigator walks through the door.

Verify your audit trail integrity

Under 21″>https://www.cloudtheapp.com/glossary-21-cfr-part-11/”>21 CFR Part 11 and QMSR, audit”>https://www.cloudtheapp.com/glossary-audit-trail/”>audit trail records in electronic systems must capture who made a change, what changed, and when. Run a sample review of your electronic quality records to confirm the audit trail is functioning correctly and has not been disabled or altered.

FDA investigators specifically test audit trail functionality in electronic systems. A system with missing or inconsistent audit trail data can elevate a minor finding into a significant observation.

When the investigator arrives

When an FDA investigator presents credentials at your facility, escort them to a private conference room, notify your inspection coordinator immediately, and offer them a clean workspace with access to the records they need.

Several practical points apply throughout the inspection:

Provide only what is requested. Do not volunteer documents or information beyond the scope of each specific request. If you are uncertain whether a document is responsive to a request, check with your quality team before providing it.

Document every request. Keep a written log of every document requested, every question asked, and every record provided. This log becomes critical if you need to prepare responses to 483 observations after the inspection closes.

Answer questions accurately. Staff who speak with investigators should answer questions directly and accurately. If they do not know an answer, saying “I’ll get you that information” is better than guessing. Inconsistent answers create complications that an honest gap would not.

Do not correct records during the inspection. If the investigator identifies an error in a document, do not modify the record during the inspection. Note the issue and address it through your CAPA system after the inspection closes.

Responding to FDA Form 483 observations

A FDA”>https://www.cloudtheapp.com/glossary-fda-form-483-inspection-observation/”>FDA Form 483 observation is a written notice of conditions that may constitute violations of the Food, Drug, and Cosmetic Act. Receiving one does not automatically lead to enforcement action. What matters is how you respond.

You have 15 business days to submit a formal written response. A strong response:

• Acknowledges the observation specifically without admitting more than the observation states
• Describes the immediate corrective action already completed
• Describes the systemic corrective action planned, with a specific timeline and responsible owner
• Includes supporting evidence where available, such as revised procedures or completed training records

FDA evaluates whether your response reflects genuine corrective action. Generic responses promising to “review procedures” without specific actions are viewed unfavorably. A response with documented, concrete corrections already initiated signals a quality system that is functioning as intended.

How an eQMS supports inspection readiness year-round

Quality teams that manage their systems in spreadsheets and shared drives spend significant time reconstructing records before an inspection and locating specific files during one. An electronic QMS centralizes document control, CAPA management, training records, complaint handling, supplier qualification, and audit management in a single system with a complete, tamper-evident audit”>https://www.cloudtheapp.com/glossary-audit-trail/”>audit trail.

When an FDA investigator requests all CAPA records for a specific product line over the past two years, your response time in a capable eQMS is measured in seconds rather than hours.

Cloudtheapp is a fully validated, AI-powered eQMS built for pharmaceutical, medical device, biotech, and food and beverage manufacturers. With 60+ applications covering every major quality process, Cloudtheapp gives quality teams the documentation depth, traceability, and system integrity to enter any FDA inspection with confidence.

Schedule”>https://www.cloudtheapp.com/demo/”>Schedule a demo to see how Cloudtheapp supports inspection readiness across your entire quality system.

Related reading

• FDA”>https://www.cloudtheapp.com/fda-qmsr-2026-the-complete-guide-to-the-quality-management-system-regulation/”>FDA QMSR 2026: The Complete Guide to the Quality Management System Regulation
• FDA”>https://www.cloudtheapp.com/fda-enforcement-trends-q1-2026-what-warning-letters-and-483s-tell-quality-teams/”>FDA Enforcement Trends Q1 2026: What Warning Letters and 483s Tell Quality Teams
• 21″>https://www.cloudtheapp.com/21-cfr-part-820-vs-qmsr-what-changed-and-what-stayed-the-same/”>21 CFR Part 820 vs QMSR: What Changed and What Stayed the Same

This post created by and appeared first on Cloudtheapp

Nonconforming material is any raw material, component, in-process product, or finished device that fails to meet specified requirements. Under both the FDA's Quality Management System Regulation (QMSR) and ISO 13485:2016, the moment a nonconformance is detected, a documented process must take over — covering how the material is identified, how it is segregated from conforming product, who reviews it, and how it is ultimately dispositioned.

This guide covers what the regulatory requirements actually say, where manufacturers get cited by FDA investigators, and how a properly configured QMS handles nonconforming material without creating documentation gaps.

What constitutes nonconforming material

A nonconforming material event can start at incoming receiving inspection, during in-process manufacturing, or at final product inspection. It can also be identified after product has been released, when a complaint, post-market audit, or field service report reveals that something distributed to customers did not meet specifications.

The scope of what triggers a nonconformance report varies by company procedure, but the regulatory minimum is clear: any product that does not conform to specified requirements must be controlled. This includes deviations from dimensions, materials, documentation requirements, label specifications, sterility requirements, or any other attribute defined in the device master record.

The regulatory framework: 21 CFR 820.90 and ISO 13485 Section 8.3

QMSR and the role of ISO 13485:2016

The QMSR, effective February 2, 2026, incorporates ISO 13485:2016 by reference under 21 CFR 820.10(b). For nonconforming product, this means ISO 13485 Section 8.3 is now legally enforceable FDA requirement in the United States. The old 21 CFR Part 820, Section 820.90, used language that tracked closely with what ISO 13485 Section 8.3 requires, so most manufacturers familiar with the old QSR will find the substantive requirements familiar. The QMSR transition does, however, add some procedural and record-keeping specificity that FDA investigators now check against.

ISO 13485 Section 8.3.1 — documented procedure requirement

Section 8.3.1 requires that the organization establish documented procedures for the control of nonconforming product. This is not a general quality system requirement — it is a specific, auditable procedure that must exist, be implemented, and produce records. FDA investigators ask to see this procedure and then verify that actual nonconformance records reflect the procedure as written.

ISO 13485 Section 8.3.2 — identification and segregation

Section 8.3.2 requires that the organization ensure nonconforming product is identified and controlled to prevent unintended use or delivery. The standard is explicit that the organization must take one of the following actions when nonconforming product is detected: take action to eliminate the detected nonconformity; authorize its use, release, or acceptance under concession; prevent its intended use or application through segregation, return, or destruction; or apply other action appropriate to the effects of the nonconformity when detected after delivery.

The key enforcement point in practice is "prevent unintended use." Physical identification — a quarantine tag, a red hold label, a locked cage — is not optional. FDA warning letters from 2024 and 2025 cite cases where nonconforming product was inadequately segregated and co-mingled with conforming product, or where the physical controls were present but not consistently applied.

ISO 13485 Section 8.3.3 — review authority and documentation

Section 8.3.3 requires that the review of nonconforming product be conducted by personnel with defined authority. The person who makes a disposition decision must have documented authority to do so. It is not enough to have a quality manager sign off generically — the procedure must define who is authorized for what disposition decisions, and the record must show that an authorized person made each specific decision.

Section 8.3.3 also requires that records be maintained describing the nature of the nonconformity, the quantity affected, the disposition decision, and the identity of the person who authorized the disposition.

ISO 13485 Section 8.3.4 — rework

Section 8.3.4 contains specific requirements for product reworked to bring it into conformance. Rework must be performed in accordance with documented instructions. After rework, the product must be re-inspected or re-verified. The potential adverse effects of rework on the product's safety and performance must be documented and reviewed. Rework that affects a device's safety profile without a corresponding safety assessment is a documented finding in multiple FDA warning letters.

Identification: catching nonconformances before product moves

The earlier a nonconformance is detected, the lower the cost and compliance impact. Most manufacturers identify nonconforming material at four points: incoming receiving inspection, in-process inspection during manufacturing, final product inspection before release, and post-release through complaints or field reports.

Incoming receiving inspection is where supplier-related nonconformances surface. Under ISO 13485 Section 7.4.3, receiving inspection records must be maintained, and any nonconformances found at receiving must be documented and dispositioned before the material enters production. Using a supplier's certificate of conformance as a substitute for incoming inspection is acceptable only when the procedure defines specific conditions under which this is permitted — and the procedure must define what happens when a later nonconformance is discovered for material that entered based on a COC.

In-process nonconformances require immediate action to prevent the material from advancing further in the production process. A nonconformance caught at subassembly is cheaper and lower-risk than the same nonconformance discovered at final inspection or after release.

Containment: preventing unintended release

Physical containment is the step most frequently cited in FDA Form 483 observations related to nonconforming material. Containment means the nonconforming material is physically separated from conforming product in a way that prevents accidental release.

Acceptable containment methods include: a dedicated quarantine area with restricted access, locked cages or cabinets for high-risk nonconformances, physical hold tags attached to the material itself, and system-level holds in the QMS that prevent lot release without disposition review. A sticker on a shelf with no physical barrier and no system control does not satisfy containment, nor does a verbal instruction to production staff.

When a nonconformance is detected after product has left the facility, the manufacturer must assess whether the nonconformance poses a risk to patients or users, determine the scope of potentially affected product (lot numbers, date ranges, distribution locations), and decide whether a field action, correction, or removal is warranted. This post-market containment assessment must be documented.

Disposition: the options and what each requires

After containment, the disposition review determines what happens to the nonconforming material. ISO 13485 Section 8.3 recognizes four primary disposition paths.

Rework. The material is brought into conformance through additional processing. Rework requires documented instructions, re-inspection after completion, and a safety assessment if there is any possibility the rework affected the device's safety or performance characteristics.

Concession (accept as-is). The material is accepted for use or release despite the nonconformance, with written authorization. A concession must define the specific nonconformance being accepted, the scope of product involved, the risk basis for accepting it, and the identity of the authorized approver. FDA investigators check that concessions are not being used as a general workaround for recurring process problems.

Return to supplier. For incoming material that does not meet requirements, return to supplier is a documented option. The supplier must be notified, and the return must be documented in the supplier quality management system. Repeated returns from the same supplier without escalation through the supplier qualification process are flagged during audits.

Scrap or destruction. The material is destroyed and removed from the production flow. Destruction must be documented — date, quantity, method, and person responsible. This is particularly important for devices where there is any possibility that scrapped material could be reintroduced into the production stream.

When nonconforming material triggers a CAPA

A single nonconforming material event does not always require a corrective action. The decision to initiate a deviation CAPA should be risk-based: if the nonconformance represents a systemic failure, a recurring pattern, a safety-critical characteristic, or a significant deviation from specification, a CAPA is required.

FDA investigators check the relationship between nonconforming material records and the CAPA system. A manufacturer that has 40 nonconformance records in a year and zero corrective action initiations will have difficulty demonstrating that their corrective action process is functioning as intended. The threshold for CAPA initiation must be defined in the procedure, and the records must show that the threshold is being applied consistently.

When a CAPA is initiated, the nonconformance record should be linked to the corrective action record. This traceability allows investigators to verify that the root cause investigation addressed the actual nonconformance and that the effectiveness check verified the corrective action worked.

What FDA investigators cited in 2024 and 2025

Published FDA warning letters and 483 observation data from 2024 and 2025 show consistent patterns in nonconforming material findings.

Nonconforming product not properly identified. FDA investigators at multiple medical device facilities found nonconforming components that lacked identification tags or hold labels, making it impossible to distinguish them from conforming product in the production area.

Disposition decisions made without documented authority. At several inspected facilities, disposition decisions were made by production supervisors or technicians not identified in the procedure as having disposition authority. The absence of documented authority is a direct Section 8.3.3 violation.

Rework not re-inspected. FDA warning letters from 2024 and 2025 cite rework operations where product was returned to conforming stock without documented re-inspection. In one case involving an orthopedic implant manufacturer, reworked components were released without a safety assessment for the effect of rework on the implant's structural integrity.

Repeat nonconformances without corrective action. FDA investigators consistently flag situations where the same nonconformance appears multiple times within a review period but no corrective action was initiated. The question asked during inspection is typically: "What is your threshold for CAPA initiation, and why was this recurring nonconformance below that threshold?"

Post-market nonconformances not assessed for field action. When complaints or post-market surveillance data revealed nonconformances in distributed product, several manufacturers failed to document a formal assessment of whether a field action was required. FDA expects a documented risk-based evaluation, not an informal determination.

How a QMS system handles nonconforming material at scale

At low volumes, a paper-based or spreadsheet-driven nonconforming material process can be managed, though it is difficult to maintain traceability and even harder to demonstrate consistency during an inspection. As production volume increases, the gaps in manual systems compound.

A well-configured eQMS handles nonconforming material by creating a digital record at the point of detection, automatically flagging the affected lot or batch in the inventory system to prevent release, routing the disposition review to the personnel with defined authority, and generating the required re-inspection task when a rework disposition is selected. The system also provides the trend analysis needed to identify recurring nonconformances that should trigger a CAPA.

Cloudtheapp includes a Nonconforming Material application that manages the full nonconformance workflow — identification, containment, disposition review, rework tracking, and CAPA linkage — within a single validated platform. Lot-level traceability means that when a post-market nonconformance is identified, the system can quickly identify all affected product and its distribution status.

The platform is validated for 21 CFR Part 820 (QMSR) and ISO 13485, with a full validation package provided for every update. If your nonconforming material process relies on spreadsheets, paper logs, or disconnected systems, schedule a demo at Cloudtheapp to see how the platform handles NCM from detection through closed-loop corrective action.

This post created by and appeared first on Cloudtheapp

Risk management is among the most consistently enforced requirements in the medical device quality system. ISO 13485:2016 and the FDA's Quality Management System Regulation (QMSR), which became effective on February 2, 2026, both treat risk management as a requirement that runs across the entire product lifecycle — from design inputs through post-market surveillance.

This article covers what risk management requires under both standards, how ISO 14971 fits into the picture, what FDA inspectors have been flagging in recent inspection cycles, and what a functional risk management program looks like in an audit-ready QMS.

What the QMSR says about risk management

The FDA finalized the QMSR in February 2024 after a multi-year harmonization effort. The regulation's central mechanism is incorporating ISO 13485:2016 by reference under 21 CFR 820.10(b). That means the ISO 13485 risk management requirements are now legally enforceable FDA requirements for U.S. medical device manufacturers.

ISO 13485:2016 uses the phrase "risk management" 33 times across its clauses. The standard requires manufacturers to document and apply a risk-based approach to design and development, production controls, purchasing decisions, corrective action, and process changes. Risk management appears as a requirement in Clause 4 (general quality management system), Clause 7 (product realization), and Clause 8 (measurement, analysis, and improvement).

The QMSR also preserves FDA-specific requirements that supplement ISO 13485. Under 21 CFR 820.10(c), FDA maintains its own design and development requirements, which manufacturers must meet alongside ISO 13485 Clause 7. For product-level risk documentation, this creates a dual obligation — and FDA inspectors check for compliance with both layers.

ISO 14971 and its role under the QMSR

ISO 14971:2019 defines the application of risk management to medical devices. Its process covers hazard identification, risk estimation, risk evaluation, risk control selection, residual risk evaluation, and overall risk-benefit analysis.

FDA does not incorporate ISO 14971 by reference within the QMSR. However, the FDA made clear in the Federal Register publication of the QMSR (February 2, 2024) that conformance to ISO 14971 is recognized as a well-documented method for satisfying the risk management requirements embedded in ISO 13485. Companies that already operate under ISO 14971 for notified body certification have methodology that maps directly to QMSR compliance. Companies that treated risk management as a design-phase activity only, handled separately from production and post-market processes, have a gap worth addressing before their next inspection.

Risk management requirements under ISO 13485

Clause 4.1 — General QMS requirements

Clause 4.1 requires that the organization apply a risk-based approach to the processes needed for the QMS itself. This is the foundation of the standard's risk philosophy: risk thinking shapes which processes receive monitoring controls and how those controls are designed.

Clause 7.1 — Planning of product realization

Clause 7.1 requires that risk management activities be included in the planning of product realization. The outputs of this planning must include identification of specific risk management activities and the records needed to demonstrate they were carried out. This is where many FDA Form 483 observations originate — companies plan risk management at a high level in their procedures but fail to generate records that trace back to individual product realization decisions.

Clause 7.3 — Design and development

Design and development is where risk management documentation is most specific. Clause 7.3 requires that risk management activities be performed as part of design planning, that risk outputs are documented with traceability to design inputs, that verification and validation activities address identified risks, and that design transfer documents include the results of risk management activities applied during development.

Clause 7.4 — Purchasing

Risk management applies to supplier selection and purchased material decisions. ISO 13485 requires that supplier selection criteria account for the risk associated with the product or process the supplier supports. This is enforced under QMSR through supplier qualification requirements that FDA investigators check against the actual qualification records.

Clause 8.5 — Improvement

CAPA processes under Clause 8.5 require that corrective and preventive actions account for the risk posed by the nonconformity being addressed. Risk assessment is a required input to any corrective action decision. High-risk deviations must be escalated and documented at a level proportionate to their risk — a requirement that FDA investigators verify by asking for the risk assessment attached to specific CAPA records.

What FDA inspectors have been flagging

FDA Form 483 observations published through 2025 and FDA enforcement data from the QMSR transition period show several repeated patterns in risk management-related findings.

Missing risk management records for legacy products. Companies transitioning from the old 21 CFR Part 820 Quality System Regulation to QMSR frequently have documented risk assessments for newer products but gaps for devices that pre-date formal ISO 14971 adoption. Under QMSR, those gaps are compliance issues.

Risk management files without traceability. FDA investigators regularly find risk management files that exist as standalone documents with no traceability to the device master record, the design history file, or the CAPA system. A risk management file must be a living record tied to the product's documentation architecture, not a submission artifact that gets filed and forgotten.

Missing residual risk evaluation. ISO 14971 requires a final residual risk evaluation after all risk controls have been implemented. FDA investigators have issued 483 observations for risk management files that document hazards and controls but never formally evaluate whether the post-control residual risk is acceptable under the manufacturer's risk criteria.

Post-market data not feeding back into the risk management file. Complaint data, field service reports, and post-market surveillance data must flow back into the risk management file. Companies that treat risk management as a pre-market activity and never update their risk management files with post-market information are consistently flagged. FDA's inspection guidance updated in February 2026 specifically calls out the post-market feedback loop as an inspection focus area.

The risk register and its practical function

A risk register is the working output of a formal risk management process. For medical device manufacturers, the risk register captures each identified hazard, the associated hazardous situation, the potential harm, the probability of occurrence, the severity of harm, the risk level before controls, the risk controls applied, and the residual risk after controls.

Under ISO 14971:2019, the risk register must be reviewed when a design change occurs, when a production process changes, when a complaint or adverse event reveals a previously unidentified hazard, or when a regulatory change alters applicable risk criteria. Companies that maintain their risk register as a static document — reviewed once at 510(k) submission and never updated — are issued 483 observations when investigators pull complaint records and ask for the corresponding risk file updates.

Risk management across the product lifecycle

Pre-market risk management

Pre-market risk management covers design and development planning, hazard identification, risk analysis, risk control selection, design verification and validation against identified risks, and risk management file outputs that feed into the 510(k) or PMA submission. The design history file must contain the risk management outputs for each design element.

Production risk management

Production-phase risk management covers manufacturing process assessments, supplier qualification decisions linked to product risk levels, in-process controls that are calibrated to the risk of the operations they monitor, and process change reviews that include a risk assessment of the change's impact on safety and performance.

Post-market risk management

Post-market risk management covers complaint analysis, adverse event investigation, audits of the production system, post-market clinical follow-up where required, and systematic updating of the risk management file based on real-world data. Gaps in post-market risk management are the most frequently unresolved finding category in FDA enforcement actions from 2024 and 2025.

CAPA and risk management — the feedback loop

Every deviation CAPA must include a risk assessment. ISO 13485 Clause 8.5.2 requires that the scope of a corrective action be proportional to the risk associated with the nonconformity. A CAPA for a labeling error on a low-risk device carries a different risk weight than a CAPA for an out-of-specification manufacturing step on an implantable device.

This connection between CAPA and risk management is the most frequently documented gap when both systems are reviewed together during an inspection. Companies often have a functioning CAPA process and a separate risk management program, but the two systems do not communicate. When an investigator asks for the risk assessment attached to a corrective action record, the record does not have one — because the risk assessment was stored in a different document and was never linked to the CAPA.

A well-configured eQMS addresses this by requiring a risk assessment as a mandatory field within the corrective action workflow. When the CAPA record cannot advance or close without a completed risk assessment, the gap is closed at the process level rather than through manual oversight.

Building a risk management program that holds up to inspection

The three most common root causes for risk management 483 observations are: risk management files that are not updated after design changes, risk assessments that exist in isolation from CAPA and complaint records, and post-market surveillance data that is analyzed separately from the risk management file rather than being used to update it.

A root cause investigation of any 483-cited risk management gap typically reveals a system-level disconnection rather than an individual documentation failure. The risk management process and the rest of the QMS need to share data, not just reference each other in procedures.

Cloudtheapp's platform includes native risk management functionality that connects risk records directly to CAPA, design control, and supplier management workflows. Risk assessments are required fields in corrective action workflows. Design change records trigger risk file review tasks. Post-market complaint data flows into risk registers without manual intervention. The platform is validated for 21 CFR Part 820 (QMSR), ISO 13485, and ISO 14971 application — which means the audit trail and traceability requirements that FDA investigators check are built into how the system operates.

If your organization is completing its transition to QMSR or building a risk management program designed to hold up to FDA scrutiny, schedule a demo at Cloudtheapp to see how the platform structures risk management across the full product lifecycle.

This post created by and appeared first on Cloudtheapp

TLDR

FDA enforcement intensity reached record levels entering 2026. Drug warning letters jumped 59% in FY 2025. Medical device warning letters rose 17% year over year. Under the new QMSR inspection framework effective February 2, 2026, early enforcement data from 93 inspections shows that Management Oversight and risk management integration are now the dominant citation areas, accounting for nearly 30% of all post-QMSR observations. The same three violations that topped the device enforcement list in 2024 — CAPA deficiencies, complaint handling failures, and supplier control gaps — remain the most cited in 2026. The pattern is not random. It signals exactly where FDA inspectors are focusing, and it tells quality teams precisely where to close gaps before the next inspection.

Q1 2026 produced a wave of enforcement data that quality teams cannot afford to ignore. FDA's transition to the Quality Management System Regulation (QMSR) on February 2, 2026 was not the only major development of the quarter. Warning letters with unprecedented language, a new draft guidance on Form 483 responses, and the launch of a unified adverse event reporting dashboard all signaled a more aggressive and integrated enforcement posture from the agency.

This article analyzes the quantitative enforcement data, the most-cited violations by process area, notable Q1 2026 warning letters, and what the emerging QMSR inspection pattern reveals about where FDA enforcement attention is heading for the rest of 2026.

The Numbers: FDA Enforcement Volume Through Q1 2026

The scale of FDA enforcement activity going into 2026 is best understood against the trajectory of the prior four years.

FDA issued 695 total warning letters across all regulated products in 2025, according to RegulatoryIQ's analysis of 2,804 deduplicated warning letters spanning January 2021 through March 2026. Of those 695 letters, approximately 54 (roughly 8%) were directed at medical device manufacturers — a 17% increase from 46 device letters in 2024, per Emergo by UL's annual CDRH review. In the drug and biologics space, FDA issued 303 warning letters in FY 2025, a 59% increase from 190 in FY 2024.

Device-specific quality system enforcement (QSR/QMSR-based letters) has surged from 6 letters in 2021 to 30 in 2025, a 5.0x increase over five years. The pace in early 2026 shows no sign of deceleration. And the transition to QMSR has not reduced enforcement volume — it has changed the language and the inspection architecture, while the underlying violation patterns remain remarkably stable.

The Top 9 Device 483 Citations in FY 2025

FDA documented 2,660 device-related Form 483 citations across 185 unique regulatory provisions in FY 2025. The concentration in the top citations was striking. The following nine citation categories represented the majority of all device observations:

CAPA procedures inadequate (21 CFR 820.100(a)): 279 observations, 10.5% of total. Complaint handling deficiencies (21 CFR 820.198(a)): 211 observations, 7.9%. Purchasing and supplier controls deficient (21 CFR 820.50): 115 observations, 4.3%. Nonconforming product control failures (21 CFR 820.90(a)): 95 observations, 3.6%. Process validation inadequate (21 CFR 820.75(a)): 93 observations, 3.5%. MDR procedures inadequate (21 CFR 803.17): 63 observations, 2.4%. CAPA documentation weaknesses (21 CFR 820.100(b)): 63 observations, 2.4%. Internal quality audits deficient (21 CFR 820.22): 57 observations, 2.1%. Device lacks required UDI (21 CFR 801.20(a)): 54 observations, 2.0%.

Source: FY 2025 FDA Inspection Observations dataset, analyzed by Hogan Lovells and GMP Insiders.

CAPA, complaint handling, and supplier controls — the top three — each appeared in 25 to 26 of the 54 device warning letters issued in 2025, per Covington and Burling's quarterly analysis. These are not new problem areas. They have topped the device enforcement list consistently since 2023. The persistence of the same violations is itself a signal: FDA is not moving on from these areas until manufacturers do.

What Triggers Escalation from 483 to Warning Letter

Not all Form 483 observations become warning letters. Understanding what drives the escalation matters as much as knowing which citations are most common.

Three patterns appear consistently in Q1 2026 enforcement actions:

Inadequate investigation scope. FDA repeatedly cites manufacturers for limiting CAPA investigations to the immediate incident rather than determining whether the root cause investigation reveals a systemic problem. The Medline Industries/NAMIC Division warning letter issued March 25, 2026, explicitly cited a CAPA record that showed complaint rates exceeding the firm's own established threshold in Q1, Q2, and Q3 of 2025, yet no action was taken. The firm's SOP itself required routing the CAPA back for additional investigation when effectiveness checks failed. FDA cited the procedural violation directly.

Weak post-market feedback loops. FDA's analysis of warning letters issued in the 12 months preceding QMSR implementation showed a 34% increase in citations related to quality system effectiveness versus procedural compliance. The agency is not just checking whether procedures exist — it is verifying that complaint data, adverse event data, and postmarket surveillance actually feed into risk management and CAPA decisions.

Inadequate 483 responses. In March 2026, FDA published a new Draft Guidance on Responding to FDA Form 483 Observations, citing inadequate responses "due to a lack or omission of relevant data, excessive amounts of data, and/or failure to address the root cause of observations." A generic corrective action promise without substantive root cause analysis will not be accepted as adequate, and will be weighed in FDA's escalation decision.

Notable Q1 2026 Enforcement Actions

Several warning letters issued in Q1 2026 carry enforcement lessons that extend beyond the specific companies cited.

Beta Bionics (January 28, 2026). CDRH issued a warning letter following a June 2025 inspection of the iLet Bionic Pancreas System. The letter cited 56 hypoglycemia complaints closed without corrective action, despite the firm's own risk analysis classifying severity as potentially fatal. Trending methodology used inflated opportunity counts to dilute complaint rates below action thresholds. CAPA effectiveness verification tested employees rather than actual device users. A cybersecurity vulnerability fix was deployed without required correction and removal reporting to FDA, and a software update categorized as a "device enhancement" was actually a safety correction. This is one of the most comprehensive SaMD enforcement actions in recent history.

Abbott Diabetes Care (January 2026). A warning letter for the FreeStyle Libre 3 Continuous Glucose Monitor cited a failure to correctly translate device design into production specifications for a third-party manufacturer. The firm also failed to define whether accuracy testing would be performed by Abbott or its contract manufacturers. Inadequate production monitoring resulted in a Class I recall associated with 7 deaths and over 860 injuries. FDA's position is unambiguous: device manufacturers retain full accountability for vendor quality.

IsoTis OrthoBiologics (February 24, 2026) and Longhorn Vaccines and Diagnostics (February 26, 2026). These two letters contain identical standardized language establishing what enforcement professionals are calling the "QMSR remediation mandate." Both firms were inspected under the old QSR in October 2025, but their warning letters — issued after QMSR took effect — include this language: "any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026." Manufacturers with open 483 observations from pre-QMSR inspections now face the same mandate.

Medline Industries / NAMIC Division (March 25, 2026). Following a December 2025 inspection, FDA cited CAPA failure (complaint rates exceeded the 15.98 CPM threshold for three consecutive quarters with no remediation), design verification deficiencies, and inadequate cleaning and safety testing. The firm subsequently initiated a removal of NAMIC Angiographic Control Syringes.

The Post-QMSR 483 Pattern: Early 2026 Data

Between February 4 and March 13, 2026, FDA completed 93 medical device inspections under the new QMSR framework. Those inspections produced 132 Form 483 observations across 52 establishments, per RegulatoryIQ's analysis of FDA's Inspectional Observation Database.

Citation language has shifted completely. 89.4% of post-QMSR observations cite ISO 13485:2016 clauses directly, not legacy 21 CFR 820 sections. Only the four OAFRs still reference 21 CFR.

Management Oversight observations account for 29.5% of all post-QMSR citations, driven primarily by ISO 13485 clauses 7.1 (product realization and risk management) and 4.1.2. Clause 7.1 alone represents 13.6% of all post-QMSR observations — the single most cited clause in the early dataset.

Inspection classification shifted: pre-QMSR inspections showed 52.7% No Action Indicated (NAI) and 43.5% Voluntary Action Indicated (VAI). In the first six weeks under QMSR, NAI dropped to 48.8% while VAI rose to 51.2%. Zero OAI classifications appear in the published early dataset. FDA is finding more objectionable conditions under QMSR but has not yet classified any as requiring official action — a pattern consistent with a transition enforcement phase.

FDA official Karen Cruz-Arenas presented the top five QMSR inspection findings at the FMMC Florida Medical Device Symposium on May 6, 2026: (1) risk management integration — firms documented risk controls in risk files but could not demonstrate implementation or verification; (2) outsourcing and purchasing controls; (3) complaint handling and postmarket integration; (4) design and development controls; (5) documentation and data integrity.

Three Patterns Quality Teams Should Act On Now

Risk management is the new primary inspection target. Under CP 7382.850, risk management processes are where investigators start and where they apply the most scrutiny. A risk management file that is incomplete, static, or disconnected from postmarket data is now the highest-risk document in your facility. Risk register maintenance must be a continuous, structured activity — not a design-phase deliverable.

Complaint handling is FDA's early-warning system. Two of the top three device violations in 2025 (CAPA and complaints) are directly connected. The enforcement pattern in multiple Q1 warning letters is identical: complaints received, logged, and closed without investigation, escalation to CAPA, or integration into risk management. FDA expects complaint data to function as a safety signal that automatically triggers risk assessment.

Supplier oversight is under increasing scrutiny. Supplier control deficiencies ranked third overall in device 483 citations. The Abbott and Royal Philips warning letters both illustrate FDA's position that manufacturers cannot delegate quality accountability to external parties. Vendor qualification documentation, testing responsibility definitions, and change notification agreements must cover every outsourced function.

How Cloudtheapp Prevents the Violations FDA Is Citing Most

Cloudtheapp is an FDA-validated, AI-powered Quality Management System platform for regulated industries including medical devices, pharmaceuticals, biotech, and food and beverage. The violation patterns driving Q1 2026 enforcement map directly to Cloudtheapp's core modules.

The CAPA module connects corrective and preventive actions to complaint records, audit findings, risk assessments, and process monitoring in a single integrated workflow. Every CAPA carries a timestamped audit trail covering investigation scope, root cause analysis, corrective action implementation, and effectiveness verification. CAPA closures require documented evidence.

The Complaint Handling module routes every complaint through structured evaluation including classification, investigation assignment, MDR eligibility assessment, and automatic escalation to CAPA and risk management when thresholds are met. Trending occurs at configurable intervals.

The Supplier Quality Management (SQM) module manages the full supplier lifecycle — qualification, approved supplier listing, audit scheduling, audit reports, and corrective action requests. Every outsourced activity is associated with documented qualification criteria.

The Risk Management module maintains a dynamic risk file linked to product design records, process changes, complaint trends, and CAPA outcomes. When complaint rates change the risk profile, the risk file is updated through a structured workflow.

All records are maintained in a validated, 21 CFR Part 11-compliant environment with electronic signatures and complete audit trails.

Want to close the gaps that FDA is citing most in 2026? Request a demo of Cloudtheapp and talk to a quality management specialist about your inspection-readiness strategy.

Frequently Asked Questions

What were the most common FDA 483 observations for medical devices in FY 2025?
The top three were CAPA procedures inadequate (279 observations, 10.5%), complaint handling deficiencies (211 observations, 7.9%), and purchasing and supplier controls deficient (115 observations, 4.3%). These three appeared in 25 to 26 of the 54 device warning letters issued in 2025.

What is the QMSR remediation mandate?
Two warning letters issued in Q1 2026 — to IsoTis OrthoBiologics and Longhorn Vaccines — include language requiring that corrective actions "must be pursuant to the QMSR requirements in effect as of February 2, 2026," even though both firms were inspected under the old QSR. Manufacturers with open 483 observations from pre-QMSR inspections face the same requirement.

How many FDA device inspections occurred under QMSR in Q1 2026?
Between February 4 and March 13, 2026, FDA completed 93 device inspections under QMSR, resulting in 132 Form 483 observations across 52 establishments. 89.4% of those observations cited ISO 13485:2016 clauses directly.

What is FDA's top QMSR inspection finding?
Risk management integration — specifically ISO 13485 Clause 7.1 — is the most cited finding, representing 13.6% of all post-QMSR observations. Firms documented risk controls but could not demonstrate implementation or verification.

What enforcement trend should quality teams watch for the rest of 2026?
Three trends warrant close monitoring: the rise in risk management integration citations under QMSR, increased scrutiny of supplier and outsourced activity oversight, and the QMSR remediation mandate requiring that all open corrective actions meet ISO 13485 standards regardless of when the original inspection occurred.

This post created by and appeared first on Cloudtheapp

TLDR

The FDA's Quality Management System Regulation (QMSR) became effective February 2, 2026, replacing the decades-old Quality System Regulation (QSR). Alongside this shift, FDA retired its Quality System Inspection Technique (QSIT) and launched a new risk-based inspection framework under Compliance Program 7382.850. Inspectors now open by reviewing your risk management file, not a checklist of four subsystems. Management reviews, internal audits, and supplier audit reports are all now fair game for FDA review. Risk management failures are explicitly listed as triggers for Official Action Indicated (OAI) classifications. If your QMS was built around the old QSIT playbook, your inspection-readiness strategy needs a serious update in 2026.

February 2, 2026 was not just a regulatory compliance deadline. It was the day FDA rewired how it inspects medical device manufacturers.

The new Quality Management System Regulation replaced the Quality System Regulation that had governed device manufacturing practices for more than 25 years. But the change that matters most for quality teams is not what the regulation says. It is how FDA investigators now walk through your facility, what records they request first, and which findings send your inspection outcome straight to Official Action Indicated.

This article walks through the new QMSR inspection framework in practical terms, from how investigators prepare before they arrive to what you should have ready the moment they do.

What Changed on February 2, 2026

The QMSR amends 21 CFR Part 820 by incorporating ISO 13485:2016 by reference. Instead of a written requirement for each element of your quality system, the regulation now points to the corresponding ISO 13485 section. The result is a shorter Part 820 text that harmonizes U.S. device quality requirements with the global standard used by regulatory authorities across Canada, Europe, Japan, and Australia.

On the same day the QMSR took effect, FDA released Compliance Program 7382.850, the new Inspection of Medical Device Manufacturers program. This document replaced both the QSIT guide and the separate compliance programs that had previously governed premarket approval (PMA) inspections and routine surveillance inspections.

The QSIT organized FDA inspections around four subsystems: Management Controls, Design Controls, Corrective and Preventive Actions, and Production and Process Controls. Under the new CP 7382.850, that structure is gone. In its place is a six-area framework driven entirely by product risk to patients and users.

How the New QMSR Inspection Framework Is Structured

The new framework organizes QMSR compliance review into six Quality Management System Areas and four Other Applicable FDA Requirements (OAFRs).

The six QMS Areas are:

• Management Oversight (includes management review records and medical device file)
• Measurement, Analysis, and Improvement (includes complaint handling, internal audits, corrective action, preventive action, and control of nonconforming product)
• Design and Development (includes design inputs, outputs, review, verification, validation, software validation, and design transfer)
• Change Control (product and process changes)
• Outsourcing and Purchasing (supplier controls)
• Production and Service Provision (manufacturing controls, identification, traceability)

The four OAFRs that apply to every inspection are: Medical Device Reporting (MDR), Reports of Corrections and Removals, Medical Device Tracking (where applicable), and Unique Device Identification (UDI).

The Two Inspection Models

FDA uses two inspection models depending on the inspection type.

Model 1 applies to non-baseline surveillance inspections, compliance follow-up inspections, for-cause inspections, Specific Product Risk Assignment (SPRA) inspections, and PMA post-market inspections. Under Model 1, the investigator selects at least one element from each of the six QMS Areas, guided by the specific risks identified for the products under review.

Model 2 applies to baseline surveillance inspections and PMA pre-approval inspections. Under Model 2, all applicable elements within each QMS Area are reviewed. This is the more comprehensive inspection model and the one that presents the highest documentation exposure for manufacturers.

How FDA Investigators Prepare Before They Arrive

This is the part most quality teams underestimate.

Under the old QSIT model, investigators generally arrived and began working through the four subsystems based on what they found on the floor. Under CP 7382.850, FDA investigators review external information before they enter your building.

That pre-inspection review includes medical device reports (MDRs), trade complaints, reports of corrections and removals for similar products, and any prior inspection history for your facility. The objective is to build a product-specific risk profile before the investigator sets foot on your manufacturing floor.

On arrival, the investigator then opens your risk management file. This is the new starting point. According to CP 7382.850, the identified product-specific risks from your file are "used to evaluate whether a manufacturer is meeting requirements." The risk management file effectively becomes the roadmap for the entire inspection.

The practical implication: if your risk management documentation is incomplete, inconsistent with your actual manufacturing practices, or has not been updated to reflect recent changes, the investigator identifies those gaps in the first hours of the inspection, and every subsequent step is colored by that finding.

What Records FDA Now Requests That Were Off-Limits Before

One of the most consequential changes under QMSR is the elimination of the record exemptions that existed under the QSR.

Under the old Quality System Regulation, FDA was explicitly prohibited from reviewing three categories of records during inspections: management review records, internal quality audit reports, and supplier audit reports. These were considered confidential quality assurance records.

The QMSR removes all three exemptions. ISO 13485 contains no such carve-outs, and when FDA incorporated ISO 13485 by reference, it carried this change directly into U.S. federal law.

Under the new framework:

• Management review records are a named element within the Management Oversight QMS Area. They are now a standard inspection item.
• Internal audit reports appear under the Measurement, Analysis, and Improvement Area. FDA investigators can request, review, and copy them.
• Supplier audit reports are subject to FDA review and are explicitly called out on FDA's QMSR FAQ page.

FDA's legacy Compliance Policy Guide (CPG Sec. 130.300), which stated that FDA "will not review or copy reports and records that result from audits and inspections of the written quality assurance program" during routine inspections, remains on FDA's website as of early 2026. FDA has not formally rescinded it. However, the page now includes a reference to the QMSR final rule, and the legal reality is that the new regulation supersedes the older policy in practice.

Quality teams should treat all three record categories as reviewable in any inspection conducted after February 2, 2026.

What Triggers a Form 483 Under QMSR

An FDA Form 483 documents inspectional observations, meaning conditions or practices the investigator observed that may constitute violations of FDA regulations. Under the new QMSR inspection framework, several categories of findings are explicitly listed as triggers for an Official Action Indicated (OAI) classification, which is the most serious outcome and the one most likely to result in a warning letter or enforcement action.

CP 7382.850 lists the following risk management failures as Situation 1 findings, meaning they automatically move the inspection toward OAI:

• Failure to establish, implement, or maintain one or more processes for risk management in product realization
• Failure to monitor, measure, analyze, and improve processes that have demonstrated adverse impact to finished product or patient safety
• Failure to adequately analyze data, or failure to use current risk information, resulting in a decision not to proceed with formal investigations or corrective actions, where that failure leads to unmitigated adverse health consequences or nonconformities
• Feedback and postmarket surveillance data not used as inputs into risk management for monitoring and maintaining product realization processes
• Failure to control design and development of product, including inadequate evaluation of changes for risk and impact prior to implementation
• Failure to ensure processes, including changes, are adequately monitored, controlled, or evaluated for risk and impact on products prior to implementation

In addition, cybersecurity has entered the inspection scope for the first time. CP 7382.850 requires investigators to assess "cyber devices" and other software-enabled medical devices for conformity with FDA cybersecurity requirements. Failure to comply is classified as a Situation 1 finding eligible for OAI treatment.

The pattern across all of these triggers is consistent: risk management failures are the new priority. Under the QSIT, design controls were the primary focus. Under CP 7382.850, the question at every step is whether risk has been identified, evaluated, controlled, and kept current.

Six High-Priority Records to Have Ready for Any QMSR Inspection

Quality teams preparing for a QMSR inspection should ensure the following records are organized, current, and retrievable within the first day of an inspection:

Risk management file. This is the document investigators read first. It must be complete, up to date, and consistent with your current manufacturing processes and product configuration.

Management review records. These are now a named inspection element. They must reflect systematic, documented review of QMS performance at planned intervals, with clear inputs, outputs, and follow-up actions.

Internal audit reports. All internal audit records, including the scope, findings, audit findings, and corrective actions taken, are now reviewable. Audits that show findings without documented closure are particularly high-risk.

CAPA records. While CAPA is no longer a standalone mandatory element in Model 1 inspections, corrective and preventive action processes appear as elements within Measurement, Analysis, and Improvement. Root cause investigation records must show genuine analysis, not just conclusion statements.

Complaint handling and feedback records. FDA investigators will look for evidence that complaints and postmarket feedback are feeding back into risk management. Complaint records that sit in a database without documented risk review are a 483 vulnerability.

Change control records. Under both the Change Control QMS Area and the Design and Development Area, any product or process change must show documented evaluation of risk and impact prior to implementation. Undocumented or inadequately evaluated changes are among the most common 483 subjects.

What QMSR Compliance Looks Like in Practice

The shift from QSIT to CP 7382.850 is a shift in philosophy, not just structure. QSIT organized compliance into boxes. CP 7382.850 asks a single question across every box: does your organization actually understand and manage product risk throughout the product lifecycle?

That question demands a quality system with living documentation. Risk management files that are updated when products change. Internal audits that reflect honest findings. Management reviews that show leadership is genuinely engaged. Supplier controls that extend to audit reports, not just approved supplier lists.

For manufacturers that have been operating under ISO 13485 for international markets, this transition is largely familiar territory. For manufacturers whose QMS was built around QSR requirements alone, the gap is material.

The specific areas that require immediate attention for most manufacturers include: aligning the risk management file structure with ISO 14971 and ensuring it is current; updating internal audit procedures to cover all six QMS Areas; and reviewing whether management review records reflect adequate depth for FDA scrutiny.

An inspection plan that maps your existing records to the six QMS Areas and four OAFRs before your next inspection is not optional. It is how you avoid being reorganized by the investigator's roadmap instead of your own.

How Cloudtheapp Supports QMSR Inspection Readiness

Cloudtheapp is an AI-powered, no-code Quality Management System platform validated for FDA 21 CFR Part 820 (QMSR), ISO 13485:2016, and ISO 9001. It is purpose-built for the inspection environment that CP 7382.850 now defines.

Every QMSR inspection priority maps directly to a Cloudtheapp module:

The Risk Management module maintains a centralized, dynamic risk file that links product risks to design controls, process changes, and corrective actions. When FDA investigators ask to see your risk management documentation, the records are traceable, timestamped, and current.

The Audits module manages internal audits with structured scope, findings, and closure workflows. All audit records are maintained with a full audit trail, making them retrievable and defensible in an FDA review.

The CAPA module ties corrective and preventive actions to root cause investigations, complaint records, and risk assessments. Every step is documented and time-stamped.

The Change Management module ensures that every product or process change goes through a documented risk evaluation before implementation, precisely the gap that produces the most common 483 observations under the new framework.

The Complaint Handling module routes customer feedback and MDR-eligible events directly into risk review workflows, closing the loop between postmarket data and risk management inputs that CP 7382.850 explicitly evaluates.

All records are maintained in a validated, 21 CFR Part 11-compliant environment with electronic signatures and a complete audit trail on every record. That is the difference between being inspection-ready and being caught reorganizing folders the morning the investigator arrives.

Ready to build a QMS that is structured for QMSR inspections from the ground up? Request a demo of Cloudtheapp and see how quality teams in medical devices, pharma, and biotech use the platform to stay continuously inspection-ready.

Frequently Asked Questions About QMSR Inspections

What is the difference between QMSR and QSR?
The Quality Management System Regulation (QMSR) replaced the Quality System Regulation (QSR) on February 2, 2026. The QMSR amends 21 CFR Part 820 to incorporate ISO 13485:2016 by reference, harmonizing U.S. medical device quality requirements with the global standard. The QSR contained prescriptive written requirements for each element of the quality system. Under QMSR, many of those requirements now point to the corresponding ISO 13485 clauses.

Can FDA review internal audit reports under QMSR?
Yes. The QMSR removed the record exemptions that previously protected internal quality audit reports, management review records, and supplier audit reports from FDA inspection. All three categories are now subject to FDA review during inspections conducted under CP 7382.850.

What is CP 7382.850?
Compliance Program 7382.850, released January 30, 2026 and effective February 2, 2026, is the new FDA compliance program manual governing inspections of medical device manufacturers. It replaced the QSIT guide and two prior compliance programs. It establishes the six QMS Areas and four OAFRs that structure all QMSR inspections.

What triggers an OAI classification under QMSR?
CP 7382.850 lists several risk management failures as Situation 1 findings that can lead to an Official Action Indicated classification, including failure to establish or maintain risk management processes, failure to use postmarket data as risk management input, and failure to evaluate changes for risk prior to implementation. Cybersecurity failures on software-enabled devices are also classified as OAI-eligible findings.

Do MDSAP participants need to prepare differently for QMSR inspections?
For manufacturers already participating in the Medical Device Single Audit Program, the transition to CP 7382.850 has limited practical impact, since the MDSAP audit process uses a similar risk-based, process-linked approach. FDA does not conduct routine surveillance inspections for MDSAP-audited manufacturers, though for-cause and compliance follow-up inspections remain in scope.

How should quality teams prepare for their first QMSR inspection?
The most important preparation steps are: review CP 7382.850 in full and map your current QMS documentation to the six QMS Areas; ensure your risk management file is complete, current, and linked to your active products and processes; update internal audit procedures to align with the new framework; and conduct mock audits using the new inspection model as the reference structure.

This post created by and appeared first on Cloudtheapp